Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq (OPTIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00234533
Recruitment Status : Completed
First Posted : October 7, 2005
Last Update Posted : May 15, 2009
Information provided by:

Brief Summary:
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.

Condition or disease Intervention/treatment Phase
Turner Syndrome Renal Insufficiency, Chronic Pituitary Diseases Dwarfism Drug: Somatropin (rDNA origin) Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method
Study Start Date : June 2004
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Intervention Details:
  • Drug: Somatropin (rDNA origin)
    Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.

Primary Outcome Measures :
  1. Number of capillary blood spot IGF-1 measurements and optimal timing of samples to assess the IGF-1 status of NutropinAq treated patients [ Time Frame: For the duration of the study ]

Secondary Outcome Measures :
  1. Factors affecting the variability of capillary IGF-1 measurements [ Time Frame: At day 0, 3 months, 5 months and 6 months after daily injections ]
  2. Precision profile of capillary versus plasma IGF-1 measurements [ Time Frame: At day 0, 3 months and 6 months after daily injections ]
  3. Auxological parameters during NutropinAq treatment [ Time Frame: After 3 months and 6 months of daily injections ]
  4. Acceptability of the NutropinAq Pen [ Time Frame: After 5 months of daily injections ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children under 18 with growth failure associated with inadequate growth hormone secretion, or Turner syndrome or chronic renal insufficiency.

Exclusion Criteria:

  • Children with closed epiphyses
  • Children with active neoplasm
  • Children with acute critical illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00234533

  Hide Study Locations
Dienst Kindergeneeskunde
Brussels, Belgium, B-1090
Dienst Kindergeneeskunde
Edegem, Belgium, B-2650
Czech Republic
Klinika Deti a Dorostu
Praha, Czech Republic, 100 34
Aalborg Sygehus Nord, Borneafdelingen
Aalborg, Denmark, 9100
Sygeh. i Ringkjobing Amt, Borneafdeling
Herning, Denmark, 7400
Helsinki University Central Hospital
Helsinki, Finland
CHU - Hôtel Dieu
Angers, France, 49033
Cabinet Médical
Bordeaux, France, 33000
CHU Grenoble
Grenoble, France, 38043
Centre Hospitalier General
Le Havre, France, 76083
CHU Timone Enfants
Marseille, France, 13385
CHU de Montpellier
Montpellier, France, 34295
Hôpital Archet 2
Nice, France, 06202
Hôpital Saint-Vincent de Paul
Paris, France, 75674
Groupe Hospitalier de Necker
Paris, France, 75743
Hôpital Charles Nicolle
Rouen, France, 76031
CHU Hautepierre
Strasbourg, France, 67100
Centre Hospitalier de Bigorre
Tarbes, France, 65013
Cabinet Médical
Toulouse, France, 31000
Hôpital des Enfants
Toulouse, France, 31059
Centre Pédiatrique Gatien de Clocheville
Tours, France, 37044
Universitätsklinikum Leipzig AöR
Leipzig, Germany, 04317
Universitätsklinikum Tübingen
Tübingen, Germany, 72076
General State Hospital of Nikaia
Athens, Greece, 18454
PA Kyriakou Children's Hospital
Athens, Greece
Azienda Policlinico - Università di Catania
Catania, Italy, 78-95123
Ospedale Policlinico
Chieti, Italy, 5-66013
Clinica Pediatrica II
Firenze, Italy, 13-50132
Il Università degli Studi di Napoli
Napoli, Italy, 4-80138
Clinica Pediatrica, Universita Federico II di Napoli
Napoli, Italy
Clinica Pediatrica
Novara, Italy, 18-28100
Clinica Pediatrica
Parma, Italy, 14-43100
Institutul de Endocrinologie C.I. Parhon
Bucuresti, Romania, Sector 1
Russian Federation
Endocrinology Research Centre RAMS, Institute of Pediatric Endocrinology
Moscow, Russian Federation
Tushino Pediatric Hospital, RMAPE Department of Endocrinology for Childhood and Adolescent Age
Moscow, Russian Federation
Il Detska Klinika
Limbova, Slovakia, 833 40
Hospital de Nens de Barcelona
Barcelona, Spain, 08009
Hospital General Universitario
Elche, Spain, 03203
Hospital Gregorio Marañón
Madrid, Spain, 28007
Hospital Parc Taulí
Sabadell, Spain, 08208
Hospital Clínico Universitario
Santiago de Compostela, Spain, 15706
Scientific-Research Institute of Endocrinology, Academy of Medical Science of Ukraine
Kiev, Ukraine
Ukrainian Scientific practical Centre of Endocrine surgery, Endocrine Organs and Tissues Transplantation
Kiev, Ukraine
United Kingdom
St George's Hospital
London, England, United Kingdom, SW17 0QT
University Hospital Wales
Cardiff, Wales, United Kingdom, 14 4XW
Sponsors and Collaborators
Study Director: Pascale Dutailly, MD Ipsen

Responsible Party: Pascale Dutailly MD, Ipsen Identifier: NCT00234533     History of Changes
Other Study ID Numbers: 2-79-58035-700
First Posted: October 7, 2005    Key Record Dates
Last Update Posted: May 15, 2009
Last Verified: May 2009

Keywords provided by Ipsen:
child development
growth hormone
inadequate growth hormone secretion
growth failure

Additional relevant MeSH terms:
Renal Insufficiency
Turner Syndrome
Gonadal Dysgenesis
Primary Ovarian Insufficiency
Renal Insufficiency, Chronic
Pituitary Diseases
Kidney Diseases
Urologic Diseases
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn
Gonadal Disorders
Endocrine System Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Hypothalamic Diseases
Brain Diseases